Given that seven out of ten prescriptions in Europe are for generics, it is in everybody’s interest to have a thriving generic industry
In Conversation
Regulators, the industry and people in charge of the public healthcare systems are all pushing for regulatory innovation. The European Commission’s (EC) work is interesting because…
Both the Spanish healthcare system and its healthcare professionals are strongly recognised worldwide, which has opened great opportunities in R&D and clinical trials for new treatments…
We believe that to concretely help patients, we need not only a traditional and pharmacological commitment but also a social and educational one
UCB has a firm commitment to innovation as evidenced by the fact that it invests 28% of its turnover in R&D.
... price erosion is such a big concern in the Spanish market ... The pricing system for generics is forcing both brands and generics to compete…
... the needs of our customers go way beyond catheters, stents or artificial pacemakers; we try to go alongside them through their particular journey with patients.
The pandemic revealed the importance of having assets like our plant within the European territory. The most important thing for Reig Jofre is ... the fact…
Organon took a portfolio of more than 60 products, 9,000+ employees and over USD 6 billion in revenue; it is a large and complex organization that…
... our R&D department, which is big and growing, participates in 80 percent of MSD’s global clinical trials, making the affiliate number one in Europe by…
The Spanish biosimilars industry is experiencing a reduction of prices, regulatory changes regarding product approval, and increased local and global competition, which is a complex topic…
... we excel in supply chain, keeping in mind that our model is B2B; our success relies on delivering products on time so that clients can…
